knowledge -WSS

knowledge

author：entertainment 2025-09-27 16:35:47 - browse：5

Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： The haunting brain science of long Covid

WSS

FDA's naming rule on biosimilars has undermined competition

A new crop of companies is reshaping the health data economy

Senate panel puts off hardest PBM reforms for another day

Abortion pill case raises question: who can sue the FDA?

Oprah kicked off a national conversation on obesity. Let's have it

Will generative AI in health care meet the fate of IBM's Dr. Watson?

hotspot

knowledge

focus

Sports medicine is finally prioritizing gender equality

Device maker Teleflex to acquire urology company for $600M

The cancer drug shortage isn’t new — and neither are the solutions

Supreme Court mifepristone arguments center on docs' right to sue

Tori Bowie and the unacceptable rates of Black maternal death

What causes rare myocarditis in young men after Covid vaccines?

Jerome Adams on the need for new antivirals for Covid

'Investigate these claims': UFO transparency at center of House hearing

In age of alternative facts, a scholarly course on calling out crap

A new crop of companies is reshaping the health data economy

entertainment

Dems pitch expanding Medicare power to negotiate drug prices

Merck drug for rare lung condition set for approval in U.S.

Readout LOUD podcast: mifepristone case, GLP

CDC Director Mandy Cohen on transparency, trust, and health

Vertex Pharmaceuticals may move headquarters in Boston

New lawsuit accuses health insurer Cigna of denying claims in bulk

leisure time

focus

focus

entertainment